Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress.

In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile.

A total of 368 participants with advanced solid tumours were enrolled, including 178 with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other tumours.

Among them, 42.7% of the participants had previously undergone five or more systemic treatment regimens.

  • In the platinum-resistant ovarian cancer cohort, the overall objective response rate (ORR) was 40.2% and the disease control rate (DCR) was 81.6%. In the 12mg/kg subgroup, the ORR reached 52.5% and the DCR was 90.0%. In participants with HER2 1+, the ORR reached 55.6% and the DCR was 88.9%.
  • As of the data cutoff date, the median follow-up time was 6.5 months, and both progression-free survival (PFS) and duration of response (DoR) had not yet matured.
  • In HER2-positive breast cancer the ORR and DCR were 67.8% and 88.1%, respectively.
  • In HER2-low breast cancer the ORR and DCR were 41.8% and 82.1%, respectively. In the 12mg/kg subgroup, the ORR and DCR were 61.5% and 88.5%, respectively.
  • In HER2-positive gastrointestinal malignancies, the ORR and the DCR were 57.1% and 91.4%, respectively.

Doctor Daphne Day from the Medical Oncology Department at Monash Health in Melbourne, Australia, stated: “HER2 amplification or overexpression has been proven to play a significant role in the occurrence and progression of breast cancer, underscoring the importance of HER2-directed therapy. IBI354 shown promising preliminary results, with meaningful objective response and disease control rates in HER2-positive and -low breast cancer. Additionally, IBI354 has demonstrated excellent clinical safety and tolerability. Existing clinical data suggest that IBI354 has substantial development potential in the breast cancer population.”

Bispecific antibody in colon cancer

The company also shared clinical data showing promising anti-tumour activity for IBI363 (a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer.

In a Phase I trial, the ORR was 21.9% and DCR was 65.6%. The median DoR was 8.1 months. The median PFS follow-up time was 7.6 months, and the median PFS was 4.1 months.

Among the 17 subjects with baseline liver metastases who underwent at least one post-baseline tumour assessment, ORR was 11.8% and DCR was 58.8%. In the 15 subjects without baseline liver metastases, ORR was 33.3% and DCR was 73.3%.

Among the 14 subjects with RAS exon 2/3/4 mutations and who had undergone at least one post-baseline tumour assessment, ORR was 21.4% and DCR was 57.1%. In the 10 subjects without RAS exon 2/3/4 mutations, ORR was 30% and DCR was 90%.

Professor Tao Zhang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, said: “Despite recent advancements in colorectal cancer treatment, challenges such as chemotherapy toxicity and resistance continue to affect patients and clinicians. As an important cytokine activating tumour-specific CD8+T cells, IL-2 is complementary to immune checkpoint inhibitors in MOA. The combination of PD-1 and IL-2 may reverse the exhaustion of tumour-specific CD8+ T cells thereby overcoming immune resistance. The PD-1/IL-2α-bias bispecific molecule IBI363, when combined with bevacizumab, has shown promising anti-tumour activity in patients with non-MSI-H/dMMR advanced colorectal cancer.”

Diana Spencer, Senior Digital Content Editor, DDW